Exact Mass: 465.2111
Exact Mass Matches: 465.2111
Found 500 metabolites which its exact mass value is equals to given mass value 465.2111
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Biotripyrrin-a
Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247. These metabolites are recognized by an anti-bilirubin monoclonal antibody, 24G7, but are neg. in the diazo reaction. (PubMed ID 9836731 ). Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247
Biotripyrrin-b
Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247. These metabolites are recognized by an anti-bilirubin monoclonal antibody, 24G7, but are neg. in the diazo reaction. (PubMed ID 9836731 ). Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247
Acalabrutinib
Benzylpenicilloyl G
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-leucine, TFA
Luminespib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
2-{5-[(2,3,4,5,6-Pentamethylbenzyl)sulfanyl]-4-phenyl-4H-1,2,4-triazol-3-yl}-3-(2-pyridinyl)acrylonitrile
Ala Phe Gln Thr
Ala Phe Thr Gln
Ala Asn Val Tyr
Ala Asn Tyr Val
Ala Gln Phe Thr
Ala Gln Thr Phe
Ala Thr Phe Gln
Ala Thr Gln Phe
Ala Val Asn Tyr
Ala Val Tyr Asn
Ala Tyr Asn Val
Ala Tyr Val Asn
Cys Cys Ile Lys
Cys Cys Lys Ile
Cys Cys Lys Leu
Cys Cys Leu Lys
Cys Asp Lys Thr
Cys Asp Thr Lys
Cys Glu Lys Ser
Cys Glu Ser Lys
Cys Ile Cys Lys
Cys Ile Lys Cys
Cys Lys Cys Ile
Cys Lys Cys Leu
Cys Lys Asp Thr
Cys Lys Glu Ser
Cys Lys Ile Cys
Cys Lys Leu Cys
Cys Lys Ser Glu
Cys Lys Thr Asp
Cys Leu Cys Lys
Cys Leu Lys Cys
Cys Arg Ser Thr
Cys Arg Thr Ser
Cys Ser Glu Lys
Cys Ser Lys Glu
Cys Ser Arg Thr
Cys Ser Thr Arg
Cys Thr Asp Lys
Cys Thr Lys Asp
Cys Thr Arg Ser
Cys Thr Ser Arg
Asp Cys Lys Thr
Asp Cys Thr Lys
Asp Phe Gly Lys
Asp Phe Lys Gly
Asp Gly Phe Lys
Asp Gly Lys Phe
Asp Lys Cys Thr
Asp Lys Phe Gly
Asp Lys Gly Phe
Asp Lys Thr Cys
Asp Thr Cys Lys
Asp Thr Lys Cys
Glu Cys Lys Ser
Glu Cys Ser Lys
Glu Lys Cys Ser
Phe Ala Gln Thr
Phe Ala Thr Gln
Phe Asp Gly Lys
Phe Asp Lys Gly
Phe Gly Asp Lys
Phe Gly Gly Trp
Phe Gly Lys Asp
Phe Gly Trp Gly
Phe Lys Asp Gly
Phe Lys Gly Asp
Phe Asn Ser Val
Phe Asn Val Ser
Phe Gln Ala Thr
Phe Gln Thr Ala
Phe Ser Asn Val
Phe Ser Val Asn
Phe Thr Ala Gln
Phe Thr Gln Ala
Phe Val Asn Ser
Phe Val Ser Asn
Phe Trp Gly Gly
Gly Asp Phe Lys
Gly Asp Lys Phe
Gly Phe Asp Lys
Gly Phe Gly Trp
Gly Phe Lys Asp
Gly Phe Trp Gly
Gly Gly Phe Trp
Gly Gly Trp Phe
Gly Ile Asn Tyr
Gly Ile Tyr Asn
Gly Lys Asp Phe
Gly Lys Phe Asp
Gly Lys Met Met
Gly Leu Asn Tyr
Gly Leu Tyr Asn
Gly Met Lys Met
Gly Met Met Lys
Gly Asn Ile Tyr
Gly Asn Leu Tyr
Gly Asn Tyr Ile
Gly Asn Tyr Leu
Gly Gln Val Tyr
Gly Gln Tyr Val
Gly Val Gln Tyr
Gly Val Tyr Gln
Gly Trp Phe Gly
Gly Trp Gly Phe
Gly Tyr Ile Asn
Gly Tyr Leu Asn
Gly Tyr Asn Ile
Gly Tyr Asn Leu
Gly Tyr Gln Val
Gly Tyr Val Gln
Ile Cys Cys Lys
Ile Cys Lys Cys
Ile Gly Asn Tyr
Ile Gly Tyr Asn
Ile Lys Cys Cys
Ile Asn Gly Tyr
Ile Asn Tyr Gly
Ile Tyr Gly Asn
Ile Tyr Asn Gly
Lys Cys Cys Ile
Lys Cys Cys Leu
Lys Cys Ile Cys
Lys Cys Leu Cys
Lys Cys Thr Asp
Lys Asp Cys Thr
Lys Asp Phe Gly
Lys Asp Gly Phe
Lys Asp Thr Cys
Lys Glu Cys Ser
Lys Glu Ser Cys
Lys Phe Asp Gly
Lys Phe Gly Asp
Lys Gly Asp Phe
Lys Gly Phe Asp
Lys Gly Met Met
Lys Ile Cys Cys
Lys Leu Cys Cys
Lys Met Gly Met
Lys Met Met Gly
Lys Met Ser Thr
Lys Met Thr Ser
Lys Ser Met Thr
Lys Ser Thr Met
Lys Thr Met Ser
Lys Thr Ser Met
Leu Cys Cys Lys
Leu Cys Lys Cys
Leu Gly Asn Tyr
Leu Gly Tyr Asn
Leu Lys Cys Cys
Leu Asn Gly Tyr
Leu Asn Tyr Gly
Leu Tyr Gly Asn
Leu Tyr Asn Gly
Met Gly Lys Met
Met Gly Met Lys
Met Lys Gly Met
Met Lys Met Gly
Met Lys Ser Thr
Met Lys Thr Ser
Met Met Gly Lys
Met Met Lys Gly
Met Ser Lys Thr
Met Ser Gln Thr
Met Ser Thr Lys
Met Ser Thr Gln
Met Thr Lys Ser
Met Thr Asn Thr
Met Thr Gln Ser
Met Thr Ser Lys
Met Thr Ser Gln
Met Thr Thr Asn
Asn Ala Val Tyr
Asn Ala Tyr Val
Asn Phe Ser Val
Asn Phe Val Ser
Asn Gly Ile Tyr
Asn Gly Leu Tyr
Asn Gly Tyr Ile
Asn Gly Tyr Leu
Asn Ile Gly Tyr
Asn Ile Tyr Gly
Asn Leu Gly Tyr
Asn Leu Tyr Gly
Asn Met Thr Thr
Asn Ser Phe Val
Asn Ser Val Phe
Asn Thr Met Thr
Asn Thr Thr Met
Asn Val Ala Tyr
Asn Val Phe Ser
Asn Val Ser Phe
Asn Val Tyr Ala
Asn Tyr Ala Val
Asn Tyr Gly Ile
Asn Tyr Gly Leu
Asn Tyr Ile Gly
Asn Tyr Leu Gly
Asn Tyr Val Ala
Gln Ala Phe Thr
Gln Ala Thr Phe
Gln Phe Ala Thr
Gln Phe Thr Ala
Gln Gly Val Tyr
Gln Gly Tyr Val
Gln Met Ser Thr
Gln Met Thr Ser
Gln Ser Met Thr
Gln Ser Thr Met
Gln Thr Ala Phe
Gln Thr Phe Ala
Gln Thr Met Ser
Gln Thr Ser Met
Gln Val Gly Tyr
Gln Val Tyr Gly
Gln Tyr Gly Val
Gln Tyr Val Gly
Arg Cys Ser Thr
Arg Cys Thr Ser
Arg Ser Cys Thr
Arg Ser Thr Cys
Arg Thr Cys Ser
Arg Thr Ser Cys
Ser Cys Glu Lys
Ser Cys Lys Glu
Ser Cys Arg Thr
Ser Cys Thr Arg
Ser Glu Cys Lys
Ser Glu Lys Cys
Ser Phe Asn Val
Ser Phe Val Asn
Ser Lys Cys Glu
Ser Lys Glu Cys
Ser Lys Met Thr
Ser Lys Thr Met
Ser Met Lys Thr
Ser Met Gln Thr
Ser Met Thr Lys
Ser Met Thr Gln
Ser Asn Phe Val
Ser Asn Val Phe
Ser Gln Met Thr
Ser Gln Thr Met
Ser Arg Cys Thr
Ser Arg Thr Cys
Ser Thr Cys Arg
Ser Thr Lys Met
Ser Thr Met Lys
Ser Thr Met Gln
Ser Thr Gln Met
Ser Thr Arg Cys
Ser Val Phe Asn
Ser Val Asn Phe
Thr Ala Phe Gln
Thr Ala Gln Phe
Thr Cys Asp Lys
Thr Cys Lys Asp
Thr Cys Arg Ser
Thr Cys Ser Arg
Thr Asp Cys Lys
Thr Asp Lys Cys
Thr Phe Ala Gln
Thr Phe Gln Ala
Thr Lys Cys Asp
Thr Lys Asp Cys
Thr Lys Met Ser
Thr Lys Ser Met
Thr Met Lys Ser
Thr Met Asn Thr
Thr Met Gln Ser
Thr Met Ser Lys
Thr Met Ser Gln
Thr Met Thr Asn
Thr Asn Met Thr
Thr Asn Thr Met
Thr Gln Ala Phe
Thr Gln Phe Ala
Thr Gln Met Ser
Thr Gln Ser Met
Thr Arg Cys Ser
Thr Arg Ser Cys
Thr Ser Cys Arg
Thr Ser Lys Met
Thr Ser Met Lys
Thr Ser Met Gln
Thr Ser Gln Met
Thr Ser Arg Cys
Thr Thr Met Asn
Thr Thr Asn Met
Val Ala Asn Tyr
Val Ala Tyr Asn
Val Phe Asn Ser
Val Phe Ser Asn
Val Gly Gln Tyr
Val Gly Tyr Gln
Val Asn Ala Tyr
Val Asn Phe Ser
Val Asn Ser Phe
Val Asn Tyr Ala
Val Gln Gly Tyr
Val Gln Tyr Gly
Val Ser Phe Asn
Val Ser Asn Phe
Val Tyr Ala Asn
Val Tyr Gly Gln
Val Tyr Asn Ala
Val Tyr Gln Gly
Trp Phe Gly Gly
Trp Gly Phe Gly
Trp Gly Gly Phe
Tyr Ala Asn Val
Tyr Ala Val Asn
Tyr Gly Ile Asn
Tyr Gly Leu Asn
Tyr Gly Asn Ile
Tyr Gly Asn Leu
Tyr Gly Gln Val
Tyr Gly Val Gln
Tyr Ile Gly Asn
Tyr Ile Asn Gly
Tyr Leu Gly Asn
Tyr Leu Asn Gly
Tyr Asn Ala Val
Tyr Asn Gly Ile
Tyr Asn Gly Leu
Tyr Asn Ile Gly
Tyr Asn Leu Gly
Tyr Asn Val Ala
Tyr Gln Gly Val
Tyr Gln Val Gly
Tyr Val Ala Asn
Tyr Val Gly Gln
Tyr Val Asn Ala
Tyr Val Gln Gly
Sarpogrelate Hydrochloride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].
TERT-BUTYL 5-((4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL)SULFONYL)-1H-INDOLE-1-CARBOXYLATE
4-METHOXYPHENYL 2-AMINO-3,6-DI-O-BENZYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
tert-Butyl (E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxo-6-heptenoate
tert-Butyl (E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-5-hydroxy-3-oxo-6-heptenoate
Mebeverine hydrochloride
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
Acalabrutinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-Pyrrolidinone, 1-(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-4-(2-methylpropyl)-, (4R)-
(1S,2R)-(-)-2-AMINOCYCLOHEX-3-ENECARBOXYLICACIDHYDROCHLORIDE
CID 24906286
Tert-Butyl 4-({[4-(But-2-Yn-1-Ylamino)phenyl]sulfonyl}methyl)-4-[(Hydroxyamino)carbonyl]piperidine-1-Carboxylate
Luminespib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
[(3S)-3-acetamido-5-[[(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-2-carboxy-3,6-dihydro-2H-pyran-3-yl]amino]-5-oxopentyl]-(diaminomethylidene)-methylazanium
(2R)-2-amino-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[(1R,2R)-2-hydroxy-1-[[(2S,4R)-4-propylpyrrolidine-2-carbonyl]amino]propyl]oxan-2-yl]sulfanylpropanoic acid
(Z,Z)-2-[[3-(2-carboxyethyl)-5-[(4-ethenyl-1,5-dihydro-3-methyl-5-oxo-2H-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methylene]-2,5-dihydro-4-methyl-5-oxo-1H-Pyrrole-3-propanoate
N-[2-(tert-butylamino)-2-oxo-1-thiophen-2-ylethyl]-N-(2-oxolanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamide
5-[[2-[4-[1-(1,3-Dioxo-2-indenylidene)ethyl]-1-piperazinyl]ethylamino]methylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione
2-[[5-[(2,6-Dimethylphenoxy)methyl]-4-ethyl-1,2,4-triazol-3-yl]thio]-1-(4-phenyl-1-piperazinyl)ethanone
2-[(1R,3R,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(1R,3R,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-6-oxo-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[(1S,3S,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
N-[(1S,3R,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]pyridine-3-carboxamide
1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(1S,3S,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-[(1R,3R,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3R,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3S,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3R,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
5-(4,6-dioxo-3-propan-2-yl-1-cyclohex-2-enylidene)-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-2H-isoxazole-3-carboxamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(1R,3R,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-[(1S,3S,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3S,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3S,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide
(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-6-oxo-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
1-[(1S)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
1-[(1R)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
[(1R)-2-[(4-chlorophenyl)methyl]-1-(cyclopropylmethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
(1E,3E)-5-(3,3-dimethyloxiran-2-yl)-3-methylhexa-1,3-dienyl-quinolinone B
(3R,4R)-4,5-dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-[(E)-2-[(2S,5S)-2-methyl-5-prop-1-en-2-yloxolan-2-yl]ethenyl]-1,3-dihydroquinolin-2-one
(2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid
YM-58790
YM-58790 is a potent antagonist of mAChR. YM-58790 binds M1, M2, M3 with Ki values of 28 nM, 260 nM, and 15 nM. YM-58790 exhibits potent inhibitory activity on bladder pressuer in reflexly-evoked rhythmic contraction in rats[1].